ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1978

Genome Wide Association Studies in SLE Predict E-Genes and Gene Expression Patterns That Inform Ancestral-Specific Molecular Pathways and Targeted Therapies

Katherine Owen1, Carl Langefeld2, Bryce Aidukaitis1, Adam Labonte1, Michelle Catalina1, Prathyusha Bachali1, Timothy D Howard3, Amrie Grammer1 and Peter E. Lipsky1, 1AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, 2Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 3Center for Genomics and Personalized Medicine Research, Wake Forest University School of Medicine, Winston-Salem, NC

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Gene Expression, GWAS, SLE and bioinformatics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Genetics, Genomics and Proteomics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Systemic lupus erythematosus (SLE) is a multi-organ autoimmune disorder with an important genetic component. Genome-wide association studies (GWAS) have linked many single nucleotide polymorphisms (SNPs) to SLE. Recently, Langefeld et al (2017) conducted a large-scale transancestral association study of SLE to identify ancestry-dependent and independent contributions to SLE risk. Here, we take African ancestry (AA) and European ancestry (EA) SLE-associated SNPs, link them to E-Genes and couple those with differentially expressed (DE) genes from SLE patients to develop a better understanding of ancestral-related molecular pathways and novel treatments unique to each ancestral group.

Methods:

The GTEx database was used to identify E-Genes from SLE-associated SNPs and their ancestry-specific SNP proxies. Ancestry-specific E-Genes were compared to DE genes from multiple SLE gene expression datasets. For both ancestral groups, E-Gene lists were examined for the significant enrichment of gene ontogeny (GO) terms, IPA and BIG-C categories, and to predict whether E-Genes were upstream regulators (UPRs). For visualization and clustering analysis, STRING-generated networks of DE E-Genes were imported into Cytoscape and partitioned with the community clustering (GLay) algorithm via the ClusterMaker2 plugin. Drug candidates targeting E-Genes, DE genes and UPRs were identified using CLUE, REST, API, IPA and STITCH.

Results:

Newly predicted E-Genes from the GTEx database were pooled by ancestry. We identified 52 AA-associated and 260 EA-associated SNPs; 1 SNP was shared across ancestries. These SNPs identified 891 distinct E-Genes, which were then compared to SLE DE datasets. We observed differential expression of 516 EA-associated E-Genes enriched in estrogen receptor signaling, neuronal signaling and cholesterol biosynthesis via IPA, and the positive regulation of synaptic transmission by GO-term enrichment. Clustering analysis showed EA E-Gene networks dominated by transcription, RNA processing, glycolysis and immune signaling. Drug candidate comparison identified 77 EA-specific drugs, including hydroxychloroquine and drugs targeting CD40LG and CXCR1/2. For AA, 48 E-Genes were DE in SLE and enriched in IPA categories for T helper cell differentiation and melatonin biosynthesis, and the GO biological process of keratinization. Clustering analysis of the AA E-Genes showed enrichment in PRRs, immune signaling and keratinocyte differentiation. AA-specific drug candidates included HDAC inhibitors, retinoids and inhibitors of IRAK4 and MAP8K4. A total of 46 DE E-Genes were shared between ancestries, with IRF7 upregulated in all SLE datasets. Drugs targeting shared E-Genes included ibrutinib, ruxolitinib and ustekinumab.

Conclusion:

The ancestral SNP-associated E-Genes and gene expression profiles outlined here illustrate fundamental differences in lupus molecular pathways between AA and EA. The results indicate that unique sets of drugs may be particularly effective at treating lupus within each ancestral group.


Disclosure: K. Owen, None; C. Langefeld, None; B. Aidukaitis, None; A. Labonte, None; M. Catalina, None; P. Bachali, None; T. D. Howard, None; A. Grammer, None; P. E. Lipsky, None.

To cite this abstract in AMA style:

Owen K, Langefeld C, Aidukaitis B, Labonte A, Catalina M, Bachali P, Howard TD, Grammer A, Lipsky PE. Genome Wide Association Studies in SLE Predict E-Genes and Gene Expression Patterns That Inform Ancestral-Specific Molecular Pathways and Targeted Therapies [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/genome-wide-association-studies-in-sle-predict-e-genes-and-gene-expression-patterns-that-inform-ancestral-specific-molecular-pathways-and-targeted-therapies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genome-wide-association-studies-in-sle-predict-e-genes-and-gene-expression-patterns-that-inform-ancestral-specific-molecular-pathways-and-targeted-therapies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology